$66.82
-1.27
(-1.87%)
As of Sep 5, 2026, 8:21 AM EDT · cached
Price history
Bristol Myers Squibb (BMY) is trading down at $66.82 (-1.87%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
About Bristol Myers Squibb
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Recent News (20)
-
6 Healthcare Stocks WORTH BUYING?! | PFE, ABT, NVS, BMY, CGC, And AMGN? Tracy Brabin (cbidNIIrPr) 6 Healthcare Stocks WORTH BUYING?! | PFE, ABT, NVS, BMY, CGC, And AMGN? Tracy Brabin (cbidNIIrPr) mshale.com
-
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
-
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
-
Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb
Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb
-
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
-
Bristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth
Bristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth
-
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now? PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now? TradingView
-
-
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now? PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now? Zacks Investment Research
-
BRC Therapeutics Appoints Biopharma Veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Au…
-
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK
-
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's role as a specialized…
-
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
-
Atrium Therapeutics Reports Second Quarter 2026 Financial Results -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- …
-
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
-
Bristol Myers Squibb to build $2.3 billion Houston campus Bristol Myers Squibb to build $2.3 billion Houston campus
-
-
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock? BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock? The Globe and Mail
-
AstraZeneca and Bristol Myers Squibb merger talks denied AstraZeneca and Bristol Myers Squibb merger talks denied
-
Market Digest: ADTN, BMY, ECL, PWR, ROL, DLR, GNRC, GEV, PLTR
Market Digest: ADTN, BMY, ECL, PWR, ROL, DLR, GNRC, GEV, PLTR
More Health Care stocks
- JNJ Johnson & Johnson
- LLY Lilly (Eli)
- MRK Merck & Co.
- PFE Pfizer
- VTRS Viatris
- ZTS Zoetis
- A Agilent Technologies
- ABBV AbbVie